Should Researchers Accept a Contract That Lets a Sponsor Delay Publication?

Is it ever acceptable to let a research sponsor postpone publication?

You are negotiating a sponsored-research agreement. The sponsor wants the right to delay any manuscript before submission. It says the extra time may be needed to review confidential information and file patent applications.

That sounds reasonable. But how long can publication be delayed? Thirty days? Ninety days? A year? Until the sponsor launches its product? Until it decides the findings are no longer commercially inconvenient?

A publication delay is not automatically problematic. Its purpose, duration, scope, and endpoint determine whether it protects a legitimate interest or becomes a mechanism for suppressing research.

Accept only delays that are limited, justified, and unable to become a veto

A temporary delay and publication suppression are not the same thing

Some publication delays serve legitimate research interests

Research findings can contain potentially patentable inventions or legitimately confidential information supplied by a sponsor. Immediate public disclosure can create legal or commercial consequences, particularly for intellectual-property protection.

A short delay may therefore allow a university technology-transfer office or sponsor to identify an invention and file appropriate patent documentation before public disclosure. It may also give the sponsor an opportunity to identify its confidential information or provide comments on a manuscript.

Historically, ICMJE editors have explicitly recognized that sponsors may have a legitimate right to review manuscripts for a defined period for patent protection while opposing arrangements that allow sponsors to withhold publication. Current ICMJE recommendations continue to emphasize that sponsor agreements should not interfere with authors' ability to publish independently.

The contract needs an endpoint

The most important feature of an acceptable delay is that researchers know when it ends.

A clause need not contain the word “veto” to operate like one. If the sponsor can keep renewing the delay until it is satisfied, researchers do not possess a meaningful independent right to publish.

There is no universal 30-day, 60-day, or 90-day rule

Researchers sometimes encounter specific review periods in institutional contracts and mistakenly treat them as universal ethical standards.

They are not.

A 2001 ICMJE editorial gave 30 to 60 days as an example of a defined sponsor review period for additional patent protection. Stanford University's current openness policy permits, in ordinary sponsored research, a short publication delay not exceeding 90 days for patenting purposes or sponsor review and comment, subject to its stated conditions.

These examples demonstrate the principle of limited delay, not a worldwide mandatory number. Your institution may use different contractual standards, and some research arrangements have special circumstances.

Multi-site research can require different publication arrangements

Large multicenter studies complicate the issue because one participating site may complete its work before the overall study is ready for publication. Immediate publication by one site could undermine the planned combined analysis.

Institutional policies may therefore permit longer restrictions for multicenter research than for ordinary sponsor review. Stanford, for example, permits a longer delay in certain multi-site clinical research arrangements, subject to conditions in its policy.

This illustrates why publication-delay clauses should be evaluated according to their actual scientific purpose rather than by applying one fixed number to every research design.

Commercial inconvenience is not the same as patent protection

A sponsor may reasonably need a short period to file a patent. Wanting to postpone publication until unfavorable findings no longer threaten sales is a different objective.

The difference becomes visible in the contract. A patent clause should connect the delay to identifiable intellectual-property activity and impose a maximum period. A commercially protective clause may instead allow delay whenever the sponsor believes publication could harm its interests.

The latter can distort the scientific record by allowing commercially favorable findings to appear while unfavorable findings remain inaccessible.

Delay can become an integrity problem when results are time-sensitive

Not every month of delay has the same consequences. Research concerning an urgent safety issue, rapidly changing public-health problem, or significant risk to participants may carry stronger reasons for prompt communication than research without comparable time sensitivity.

Researchers should therefore consider not only the contractual maximum but also whether exercising the delay could cause harm or materially distort decisions being made in the meantime.

Legal, regulatory, ethical, and participant-safety obligations may also affect what information can be delayed. A publication contract should not be assumed to override independent reporting obligations.

Publication delay affects more than academic careers

Researchers may understandably worry that a sponsor-imposed delay will postpone a dissertation, promotion case, grant application, or subsequent project. Those consequences matter.

But the larger concern is the completeness and timeliness of the research record. Other researchers may unknowingly duplicate work. Systematic reviews may lack relevant evidence. Clinicians, policymakers, or other decision-makers may act on an incomplete literature.

Publication independence is therefore not simply an academic privilege. It helps prevent interested parties from selectively determining when evidence becomes visible.

The delay should not give the sponsor control over scientific content

A sponsor may use a review period to identify confidential information, patentable inventions, factual errors, or scientific concerns. Researchers should consider legitimate comments.

However, the end of the review period should not depend on investigators accepting sponsor-requested changes to conclusions. Otherwise, a nominal delay clause becomes a mechanism for editorial control.

The distinction between reviewing a manuscript before publication and approving it should therefore be explicit in the agreement.

Current ICMJE guidance emphasizes independent publication rights

ICMJE advises authors to avoid agreements with for-profit and nonprofit sponsors that interfere with access to study data or with authors' ability to analyze and interpret the data and prepare and publish manuscripts independently when and where they choose. It also states that policies dictating where authors may publish violate academic freedom.

ICMJE further recommends that published articles report any sponsor restrictions regarding submission for publication. Editors may request the underlying agreements confidentially.

This makes publication restrictions relevant not only to contract negotiation but also to journal transparency.

Negotiate before the sponsor knows the results

Publication rights are easiest to negotiate while everyone is still discussing hypothetical findings.

Once an unfavorable result exists, the sponsor's incentives may change. Researchers who have already signed a broad delay clause may then discover that their practical independence is much narrower than they assumed.

Institutional research or contracts offices should therefore review publication provisions before researchers commit to the project. A scientifically exciting study can become considerably less attractive if the sponsor retains control over when the evidence is allowed to exist publicly.

A delay must never quietly become permanent suppression

A contract allowing a sponsor to postpone publication indefinitely is functionally close to a contract allowing the sponsor to prevent publication.

The neighboring question of whether researchers should ever accept a sponsor's right to prevent publication altogether therefore represents the critical boundary. A genuine delay ends. A veto does not.

How a reasonable patent delay can become an unreasonable publication restriction

Now imagine the contract instead permits the sponsor to extend the delay whenever publication could harm its “commercial interests,” with no maximum duration. Although both provisions are called publication delays, the second can operate as an indefinite publication veto.

Common mistakes when negotiating publication delays

Judge the clause by what happens when the sponsor wants the paper withheld

A publication provision looks easy to accept while everyone expects favorable findings. Test it against the harder scenario: what happens if the sponsor strongly opposes publication?

The safest publication clause is one whose operation remains clear even when the sponsor would strongly prefer the findings never to appear.

What should you check before accepting a publication-delay clause?

Frequently asked questions about sponsor publication delays

A legitimate publication delay must actually end

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.